Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
Portfolio Pulse from
Amgen's experimental obesity drug showed promising results in a mid-stage trial, with patients losing up to 20% of their weight after a year without plateauing. However, these results are at the lower end of Wall Street's expectations.
November 26, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amgen's obesity drug trial results show up to 20% weight loss, but fall short of Wall Street expectations, potentially impacting stock performance.
The trial results are significant as they demonstrate the drug's effectiveness, but falling short of expectations could lead to negative sentiment among investors, potentially impacting Amgen's stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100